News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,549 Results
Type
Article (39540)
Company Profile (327)
Press Release (655682)
Section
Business (206278)
Career Advice (2009)
Deals (35691)
Drug Delivery (89)
Drug Development (81920)
Employer Resources (170)
FDA (16142)
Job Trends (14944)
News (348493)
Policy (32655)
Tag
Academia (2538)
Alliances (49834)
Alzheimer's disease (1265)
Approvals (16103)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11682)
Biotechnology (232)
Breast cancer (189)
Cancer (1377)
Cardiovascular disease (112)
Career advice (1674)
Cell therapy (283)
Clinical research (65564)
Collaboration (493)
Compensation (266)
COVID-19 (2551)
C-suite (110)
Data (1398)
Diabetes (174)
Diagnostics (6181)
Earnings (85810)
Employer resources (148)
Events (112100)
Executive appointments (397)
FDA (16825)
Funding (427)
Gene therapy (195)
GLP-1 (607)
Government (4349)
Healthcare (18739)
Infectious disease (2644)
Inflammatory bowel disease (111)
Interviews (313)
IPO (16522)
Job creations (3672)
Job search strategy (1427)
Layoffs (422)
Legal (7887)
Lung cancer (197)
Lymphoma (98)
Manufacturing (208)
Medical device (13222)
Medtech (13227)
Mergers & acquisitions (19330)
Metabolic disorders (458)
Neuroscience (1589)
NextGen Class of 2024 (6526)
Non-profit (4481)
Northern California (1700)
Obesity (260)
Opinion (183)
Patents (117)
People (57135)
Phase I (20421)
Phase II (28923)
Phase III (21443)
Pipeline (514)
Postmarket research (2566)
Preclinical (8677)
Radiopharmaceuticals (244)
Rare diseases (262)
Real estate (5979)
Regulatory (21846)
Research institute (2323)
Resumes & cover letters (349)
Southern California (1465)
Startups (3608)
United States (15327)
Vaccines (567)
Weight loss (183)
Date
Today (38)
Last 7 days (581)
Last 30 days (2304)
Last 365 days (35549)
2024 (35388)
2023 (40473)
2022 (51632)
2021 (56244)
2020 (54473)
2019 (46901)
2018 (35314)
2017 (32507)
2016 (31947)
2015 (38017)
2014 (31842)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (723)
Arizona (197)
Asia (38200)
Australia (6199)
California (3832)
Canada (1453)
China (310)
Colorado (173)
Connecticut (179)
Europe (82576)
Florida (540)
Georgia (135)
Illinois (387)
Indiana (225)
Maryland (636)
Massachusetts (3003)
Michigan (173)
Minnesota (292)
New Jersey (1113)
New York (1090)
North Carolina (786)
Northern California (1700)
Ohio (146)
Pennsylvania (926)
South America (1105)
Southern California (1465)
Texas (555)
Utah (108)
Washington State (404)
695,549 Results for "hanx biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience has announced that its collaborative work with HanX Biopharmaceutical Co., Ltd. (“HanX”), employing a unique and broad portfolio of preclinical modeling in support of HanX’s successful FDA Investigational New Drug (IND) application, has been published in Scientific Reports, a journal within the Nature portfolio.
August 22, 2023
·
4 min read
HanX Biopharmaceuticals announces HX009 IND approval from FDA
Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients with relapsed/refractory Lymphoma.
May 22, 2023
·
2 min read
BioMidwest
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.
June 20, 2024
·
5 min read
Press Releases
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
December 11, 2024
·
4 min read
BioMidwest
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.
June 13, 2024
·
5 min read
Deals
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.
January 4, 2024
·
5 min read
Press Releases
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
December 11, 2024
·
4 min read
Bio NC
KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions
KBI Biopharma, Inc., a JSR Life Sciences company and cGMP contract development and manufacturing organization, and Argonaut Manufacturing Services, Inc., a cGMP contract manufacturing organization serving the biopharmaceutical and diagnostics industries, announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions.
January 16, 2024
·
4 min read
Policy
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock, preferred stock purchase rights and Series K preferred stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.
January 26, 2024
·
5 min read
Press Releases
Biopharmaceutical Market Size to Reach USD 643.9 Billion by 2032, Impelled by Advancements in Biotechnology
Biopharmaceutical Market Outlook 2024-2032:
August 1, 2024
·
9 min read
1 of 69,555
Next